Week 349 Review - Last week's blip got back, but only just

Not a bad week, with some reasonable gains making up for last week's losses. The deficit between portfolio cost and value narrowed by £3,033 to £74,090 and portfolio value increased to £105,681.

Biggest loser was APAX:Apax Global Alpha, but that was because I switched my monthly regular investment to this when iShares Physical Gold got so expensive I didn't want to buy any more. The tiny £130 investment plus spread meant a drop of 16% despite the price not dropping that much.

I think almost every week I talk about BLU:Blue Star Capital being a yo-yo share, and this week is no exception, dropping 14% as traders baled out.

SBTX:SkinBioTherapeutics fell another 5% and I suspect will continue to do so until there is some positive news.

TRX:Tissue Regenix has been quietly sneaking upwards, and another 5% this week saw my losses reduced to 62%.

PLUS:Plus500 is getting so close to being in profit. This week they climbed 6% and are now only down by 2% so I'm very hopeful of them being green by the end of the week.

HUM:Hummingbird Resources have stayed static despite the boom in gold price, but this week they gained 9%, but they still need to double from here before I break even.

Share of the Week was DDDD:4D Pharma which climbed 11% as it appears out big seller may be out, and shorters are beginning to close their positions. My last purchase was at 56p so still short of bringing that into profit and still 50% down on my purchase price, but creeping upwards.

Staying just above the injection line

Still dragging the trend line steeper downwards

Here's the ISA and shares portfolio after week 37 of year 7.

			Weekly Change
Cash	£18.30		+£0
Portfolio cost	£82,598.82		+£0
Portfolio sell value (bid price-commission)	£47,418.66	(-42.6%)	+£1,000.88
Potential profits	£2,415.29		+£0
Yr 7 Dividends	£10,425.77		+£0
Yr 7 Profit from sales	£3,664.29		+£0
Yr 7 projected avg monthly profit	£1,646.67	(44.7%)	-£45.74
Total Dividends	£11,768.92		+£0
Total Profit from sales	£27,788.23		+£0
Average monthly cash profit	£487.29	(13.2%)	-£1.40
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	89%		+0%

JLP:Jubilee Metals stayed flat so no change in potential profits, and reasonable rise of £1,000 in value. Long term performance looking great after the dividend of PBX:Probiotix shares.

Mirrors the combined chart

Ditto

The SIPP looks like this after week 333 overall and week 21 of year 7.

			Weekly Change
Cash	£35.28		+£1.48
Portfolio cost	£94,798.22		+£128.22
Portfolio sell value (bid price - commission)	£57,328.74	(-39.5%)	+£1,906.61
Potential profits	£249.55		+£41.48
Yr 7 Dividends	£10,557.68		+£0
Yr 7 Interest	£0		+£0
Yr 7 Profit from sales	£297.22		+£0
Yr 7 projected avg monthly profit	£2,222.74	(50.5%)	-£111.20
Total Dividends	£13,762.07		+£0
Total Interest	£0.20		+£0
Total Profit from sales	£24,021.85		+£0
Average monthly cash profit	£479.90	(10.9%)	-£1.45
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	70%		+0%

Potential profits up slightly thanks to CAML:Central Asia Metals, and almost £2,000 improvement in value. Portfolio cost increased by £128 after the regular investment in APAX:Apax Global Alpha.

My two accounts are too similar as the charts all look the same. I probably ought to have kept the more risk investments in my ISA, but I fear it's too late for that now. As I focus my SIPP on more stable dividend-paying shares in the future they should diverge, although I don't really want to reduce my OPTI:Optibiotix holding which might bring them back into line if it takes off.

So close to crossing the trend line

The trading account looks like this after week 299 overall and week 39 of year 6.

			Weekly Change
Cash	£259.74		+£0
Portfolio cost	£2,374.14		+£0
Portfolio sell value (bid price - commission)	£933.68	(-60.7%)	+£126.38
Potential profits	£0.00		+£0
Year 6 Dividends	£0.00		+£0
Year 6 Profit	£0.00		+£0
Yr 6 projected avg monthly profit	£0.00	(0%)	+£0
Dividends	£60.10		+£0
Profit from sales	£937.88		+£0
Average monthly cash profit	£14.46	(7.3%)	-£0.05
(Sold stocks profit + Dividends - Fees / Months)

Excellent week with most shares significantly up, and one of the highest weekly increases ever. Still a hell of a way from being able to sell anything though.

Nudging up. Will it last?

Well above the trend line so feeling positive.

Late writing up after Easter. Still waiting on news for my big holdings, but no sign of anything coming soon.

Week 348 Review - Recovery stalled but not by much

Generally not a bad week, but a small drop in OPTI:Optibiotix resulted in the deficit between cost and value widening by £2,318 to £77,123 and overall value dropping to £102,830.

There were no shares that dropped by 5% or more this week.

SMS:Smart Metering Systems has been very slowly recovering, and is up 5% this week and only 13% down since I bought it. There is hope that by my 12 month review point in August, they will have paid nice dividends and at least be in the black. I will be selling them as they have fallen well down the magic formula list, mainly due to lower earnings.

BLU:Blue Star Capital continue to be very volatile, but increased by 9% this week after good news from one of their eSports companies. They are 36% down and could get into profit this summer as one decent RNS about SatoshiPay is likely to cause a spike.

CAML:Central Asia Metals have always been one of my favourite companies and I feel bad about how often I sell them, but it's great to be back invested and there was good news on production and dividend this week resulting in a big climb. I'm not exactly sure how much as I cocked up the snapshot last week, but they are now 14% up and making £153 potential profit. I hope this time I'm strong enough to keep these for the giant dividend and resist the temptation to sell.

Share of the Week is JLP:Jubilee Metals which climbed a magnificent 44% of my purchase price and are now 277% up and making £2,415 potential profit. I still have nagging doubts about whether they will ever pay a dividend and not find a way to screw the shareholders, but plan to hold long and strong if I can just avoid temptation to sell some.

The drop wasn't enough to put us back below the injection line

Still well below the trend line though

Here's the ISA and shares portfolio after week 36 of year 7.

			Weekly Change
Cash	£18.30		-£7.50
Portfolio cost	£82,598.82		+£0
Portfolio sell value (bid price-commission)	£46,417.78	(-43.8%)	-£1,040.09
Potential profits	£2,415.29		+£380.00
Yr 7 Dividends	£10,425.77		+£0
Yr 7 Profit from sales	£3,664.29		+£0
Yr 7 projected avg monthly profit	£1,692.41	(45.9%)	-£48.82
Total Dividends	£11,768.92		+£0
Total Profit from sales	£27,788.23		+£0
Average monthly cash profit	£488.69	(13.3%)	-£1.46
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	89%		+0%

Potential profits up £380 thanks to JLP:Jubilee Metals, and cash down £7.50 because I forgot to take off last month's ISA fee so there are 2 lots of £3,75 this month. Portfolio down just over £1,000 thanks to a drop in OPTI:Optibiotix.

Still just above the injection line

Well below the trend line which nothing seems able to reverse

The SIPP looks like this after week 332 overall and week 20 of year 7.

			Weekly Change
Cash	£33.80		-£16.66
Portfolio cost	£94,670.00		+£0
Portfolio sell value (bid price - commission)	£55,293.91	(-41.6%)	-£1,264.63
Potential profits	£207.67		+£149.08
Yr 7 Dividends	£10,557.68		+£0
Yr 7 Interest	£0		+£0
Yr 7 Profit from sales	£297.22		+£0
Yr 7 projected avg monthly profit	£2,333.94	(53.2%)	-£126.64
Total Dividends	£13,762.07		+£0
Total Interest	£0.20		+£0
Total Profit from sales	£24,021.85		+£0
Average monthly cash profit	£481.35	(11.0%)	-£1.67
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	70%		+0%

Potential profits up mainly thanks to CAML:Central Asia Metals, but also a small rise in iShares Physical Gold Fund. Cash down by monthly fee and value down mainly due to OPTI:Optibiotix.

As with the ISA, just above the injection line thanks to last week's huge "dividend"

Also as with the ISA, well below the trend line which is still dropping after over a year.

The trading account looks like this after week 298 overall and week 38 of year 6.

			Weekly Change
Cash	£259.74		+£0
Portfolio cost	£2,374.14		+£0
Portfolio sell value (bid price - commission)	£807.30	(-66.0%)	-£13.30
Potential profits	£0.00		+£0
Year 6 Dividends	£0.00		+£0
Year 6 Profit	£0.00		+£0
Yr 6 projected avg monthly profit	£0.00	(0%)	+£0
Dividends	£60.10		+£0
Profit from sales	£937.88		+£0
Average monthly cash profit	£14.51	(7.3%)	-£0.05
(Sold stocks profit + Dividends - Fees / Months)

DDDD:4d Pharma continues to slide, so yet another drop in value.

Above the lowest low but not by much

Miraculously still above the trend line making me hope we've bottomed out.

Basically this was another week of the same dismal slide that's been happening almost every week for over a year. It's very hard to keep up any sort of enthusiasm to write the same sob story every week. Every bit of good news has just been a blip and reversed in a few weeks. I know that one day the news will be so good we'll see a re-rate, certainly for OPTI:Optibiotix and DDDD:4d Pharma. The problem is, these are by far my biggest 2 holdings and they are both being mercilessly hammered and have been for over a year. I'm just tired of waiting for the day when these shares live up to my expectations. I'm still confident it will happen, but the journey hasn't been a pleasant one. Others will time their investment much better than mine, and good luck to them. I clearly got over-excited way too early when a "wait and see" approach would have been far more lucrative. We live and learn!

Week 347 Review - Dreadful week but massive Optibiotix dividend boosts morale

In terms of share price performance this week was utterly terrible. Some recent recoveries were obliterated with huge drops and the deficit between cost and value widened by £8,000 to £74,805. Fortunately the value of the shares dividend from OPTI:Optibiotix spinning off PBX:Probiotix meant the portfolio value increased to £105,172.

The biggest loser was SBTX:SkinBioTherapeutics after utterly dreadful interim results. They were worse than utterly dreadful, they were catastrophic. The problem wasn't necessarily just that sales of their AxisBiotix were so pitiful, but the expectations that had been built up that they were much better. As a result the share price collapsed by 34% plunging my holding from small profit to big loss.

Next disaster was the final results for DDDD:4D Pharma. No surprises here - we know there is no income and we know they have spent big, but despite this being known, the share price plummeted by 9% in my ISA and 12% of purchase price in my SIPP to wipe out all the gains following the great Oncology trial results.

I couldn't resist being one of the first people to trade PBX:Probiotix Health after their launch, so I put £350 into my AJ Bell SIPP and bought 2,075 shares at 21.2p costing £449.85. Needless to say with such a small amount, my holding is down 6% on commission and spread.

IQE:IQE continued to fall after rubbish results and lost another 5% this week to go 75% down and remove any hope of being able to sell them for years.

OPTI:Optibiotix also slipped 5% and that 3p drop made up a big chunk of this week's losses. We'd better get some good news soon as I'm fed up of these massive losses. I'm down nearly half of my investment value so it's no wonder things look so bad on my charts.

There was a little good news with FXPO:Ferrexpo climbing 7% and POLY:Polymetal climbing 9% as it increasingly looks like the war in Ukraine isn't impacting the companies as severely as initially thought. That could reverse very quickly though.

Share of the Week is JLP:Jubilee Metals which has been slipping recently but climbed 11% of my purchase price this week. I'm hoping we'll see a gradual rise from these levels.

That looks great doesn't it - until you see that the value only went up half as much as the cost. We are back above the injection line now, which is brilliant.

That's more of a realistic picture. Not the worst deficit ever but not far from it and well below the trend line.

Here's the ISA and shares portfolio after week 35 of year 7.

			Weekly Change
Cash	£25.80		+£0
Portfolio cost	£82,598.82		+£10,403.61
Portfolio sell value (bid price-commission)	£47,457.87	(-42.5%)	-£3,554.45
Potential profits	£2,035.29		+£100.00
Yr 7 Dividends	£10,425.77		+£10,403.61
Yr 7 Profit from sales	£3,664.29		+£0
Yr 7 projected avg monthly profit	£1,741.23	(47.2%)	+£1,274.73
Total Dividends	£11,768.92		+£10,403.61
Total Profit from sales	£27,788.23		+£0
Average monthly cash profit	£490.15	(13.3%)	+£128.88
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	89%		+24%

Massive drop in value if you take away the £10,403 dividend. I've accounted for the free PBX:Probiotix shares as a cash dividend that I then re-invest in the shares at IPO price of 21p. In the ISA and share accounts I end up with 49,541 shares worth £10,403 which does wonders for my long term performance taking it to 13.3%. I think this is a better way of accounting for the share dividend that having it as a zero cost share, as there would be no way to monitor the percentage value increase or decrease, and it has been described as a dividend.

Back above injection line.

Well below trend line once again

The SIPP looks like this after week 331 overall and week 19 of year 7.

			Weekly Change
Cash	£50.46		-£82.67
Portfolio cost	£94,670.00		+£10,893.57
Portfolio sell value (bid price - commission)	£56,558.54	(-40.3%)	-£4,350.18
Potential profits	£58.59		-£56.22
Yr 7 Dividends	£10,557.68		+£10,461.11
Yr 7 Interest	£0		+£0
Yr 7 Profit from sales	£297.22		+£0
Yr 7 projected avg monthly profit	£2,460.58	(56.1%)	+£2,381.72
Total Dividends	£13,762.07		+£10,461.11
Total Interest	£0.20		+£0
Total Profit from sales	£24,021.85		+£0
Average monthly cash profit	£483.02	(11.0%)	+£135.90
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	70%		+19%

This one is more complicated because of the cash injection and purchase of PBX:Probiotix shares in addition to the 49,732 I'm due as the dividend. Long term performance increased to 11% but potential profits dropped £56 which is all the SBTX:SkinBiotherapeutics losses.

Same story as the ISA

We were above the trend line so briefly and now well below it.

The trading account looks like this after week 297 overall and week 37 of year 6.

			Weekly Change
Cash	£259.74		+£0
Portfolio cost	£2,374.14		+£0
Portfolio sell value (bid price - commission)	£820.60	(-65.4%)	-£95.84
Potential profits	£0.00		+£0
Year 6 Dividends	£0.00		+£0
Year 6 Profit	£0.00		+£0
Yr 6 projected avg monthly profit	£0.00	(0%)	+£0
Dividends	£60.10		+£0
Profit from sales	£937.88		+£0
Average monthly cash profit	£14.56	(7.4%)	-£0.05
(Sold stocks profit + Dividends - Fees / Months)

Massive drop for DDDD:4D Pharma saw a £95 fall in value and things are looking bleak again

The short rise has been reversed

Amazingly still above the trend line

So a mixed bag of a week. The PBX:Probiotix allocation is provisional as they haven't turned up in my account yet, but if I've done my sums right then they should be accurate. I'm certain OPTI:Optibiotix will continue to suffer until there is positive news on SweetBiotix. The recent research not from Cenkos values the company at 4 times the current share price. That would put me £100k in profit, so I really hope it comes to pass.

Meanwhile I got Covid this morning so writing this with a headache and streaming nose and sore throat. I think it's time for bed...